Abstract
It has been shown that the incubation of human plasma with urokinase at a concentration sufficient to cause rapid lysis of the clots formed on the addition of thrombin does not give rise to the production of measurable concentrations of non-clottable fibrinogen breakdown products. Also, breakdown products could not be detected in the course of experiments in vivo when urokinase was administered to monkeys and only in very low concentrations when a fibrinolytic state was induced by exercise in three healthy human volunteers. In contrast, high concentrations of breakdown products were found after thrombin infusion into monkeys.
It is concluded that circulating fibrinogen is not readily broken down into non-clottable products by the fibrinolytic enzymes, and that normal animals and healthy human subjects do not have substantial deposits of fibrin that are available for breakdown during a fibrinolytic episode. The presence of breakdown products in the circulation is therefore likely to be indicative of the fibrinolytic response to an initial coagulation event.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bonnar J., Davidson J. F., Pidgeon C. F., McNicol G. P., Douglas A. S. Fibrin degradation products in normal and abnormal pregnancy and parturition. Br Med J. 1969 Jul 19;3(5663):137–140. doi: 10.1136/bmj.3.5663.137. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Das P. C., Allan A. G., Woodfield D. G., Cash J. D. Fibrin degradation products in sera of normal subjects. Br Med J. 1967 Dec 23;4(5581):718–720. doi: 10.1136/bmj.4.5581.718. [DOI] [PMC free article] [PubMed] [Google Scholar]
- FERREIRA H. C., MURAT L. G. An immunological method for demonstrating fibrin degradation products in serum and its use in the diagnosis of fibrinolytic states. Br J Haematol. 1963 Jul;9:299–310. doi: 10.1111/j.1365-2141.1963.tb06554.x. [DOI] [PubMed] [Google Scholar]
- Fearnley G. R., Chakrabarti R., Evans J. F. Fibrinolytic and defibrinating effect of phenformin plus ethyloestrenol in vivo. Lancet. 1969 May 3;1(7601):910–914. doi: 10.1016/s0140-6736(69)92545-8. [DOI] [PubMed] [Google Scholar]
- Gallimore M. J., Shaw J. T. Some aspects of fibrin clot lysis and its inhibition by human serum. Thromb Diath Haemorrh. 1967 Aug 15;18(1-2):101–113. [PubMed] [Google Scholar]
- Gallimore M. J., Shaw J. T. The influence of various plasma components on the lysis of dilute human blood clots. Thromb Diath Haemorrh. 1969 Nov 15;22(2):223–233. [PubMed] [Google Scholar]
- Gormsen J. Fibrinolytic activity and haemagglutination inhibition immunoassays. Scand J Haematol. 1970;7(4):261–273. doi: 10.1111/j.1600-0609.1970.tb01897.x. [DOI] [PubMed] [Google Scholar]
- Melliger E. J. Detection of fibrinogen degradation products by use of antibody coated latex particles. The possibilities and limits of the method. Thromb Diath Haemorrh. 1970 May 31;23(2):211–227. [PubMed] [Google Scholar]
- Merskey C., Kleiner G. J., Johnson A. J. Quantitative estimation of split products of fibrinogen in human serum, relation to diagnosis and treatment. Blood. 1966 Jul;28(1):1–18. [PubMed] [Google Scholar]
- Thomas D. P., Niewiarowski S., Myers A. R., Bloch K. J., Colman R. W. A comparative study of four methods for detecting fibrinogen degradation products in patients with various diseases. N Engl J Med. 1970 Sep 24;283(13):663–668. doi: 10.1056/NEJM197009242831301. [DOI] [PubMed] [Google Scholar]